Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-11-24 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
信息披露暂缓与豁免管理制度（2025年11月）
Governance Information Classification · 95% confidence The document is titled '信息披露暂缓与豁免管理制度' which translates to 'Information Disclosure Delay and Exemption Management System' for 健帆生物科技集团股份有限公司. It outlines internal policies and procedures regarding the delay and exemption of information disclosure, including legal references, internal approval processes, confidentiality commitments, and responsibilities. It does not contain financial statements, earnings data, or shareholder voting results. It is a governance-related internal policy document rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Governance Information (CGR). The document length is 4327 characters, which is not extremely short, and it is not an announcement of a report publication but a detailed internal governance policy.
2025-11-24 Chinese
第五届监事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 24th meeting of the 5th Supervisory Board of the company. It details the meeting attendance, the agenda items discussed, and the voting results. The content focuses on governance matters such as organizational structure adjustments and the abolition of supervisory meeting rules. It references compliance with company law and stock exchange regulations. The document is an official announcement of board-level decisions rather than a full report or detailed financial disclosure. It is not a full Annual Report, Interim Report, or Audit Report. It is not a call transcript, earnings release, or capital update. It is not a proxy solicitation or voting results declaration. The document fits best under Board/Management Information (MANG) as it announces changes in the company's governance structure and supervisory board decisions.
2025-11-24 Chinese
关于不向下修正健帆转债转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the board of directors of 健帆生物科技集团股份有限公司 regarding the decision not to downward adjust the conversion price of its convertible bonds (健帆转债). It details the history of the convertible bond issuance, listing, conversion price adjustments, and the specific terms and conditions under which the conversion price can be downwardly adjusted. The document also states the board's decision not to adjust the conversion price at this time and outlines the timeline for potential future adjustments. This is a regulatory announcement about the company's convertible bond pricing and related corporate actions, not a full financial report, earnings release, or management discussion. It is a formal disclosure related to capital structure and financing activities, specifically about convertible bond terms and adjustments. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5135 characters) and detailed content support that this is a substantive announcement rather than a brief notice or report publication announcement.
2025-11-24 Chinese
关于预计触发转股价格向下修正条件的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company regarding the potential triggering of a downward adjustment to the conversion price of its convertible bonds. It includes extensive historical data on bond issuance, conversion price adjustments, and the conditions under which the conversion price may be adjusted downward. The document is an announcement about a specific event related to convertible bonds and their conversion price adjustment conditions, not a full financial report or earnings release. It is regulatory in nature, providing investors with information about bond terms and potential price adjustments, but it does not contain financial statements or comprehensive financial analysis. Therefore, it fits best into the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit into more specific categories.
2025-11-17 Chinese
关于不向下修正健帆转债转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the board of directors of 健帆生物科技集团股份有限公司 regarding the decision not to downward adjust the conversion price of its convertible bonds (健帆转债). It details the history of the convertible bond issuance, listing, conversion price adjustments, and the specific terms and conditions under which the conversion price may be adjusted downward. The document also states the board's decision on a specific date not to adjust the conversion price downward despite the triggering conditions being met. This is a regulatory announcement about the convertible bond's conversion price adjustment status and related corporate actions, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive information and detailed disclosures about the convertible bond and board decisions. The content fits best under Capital/Financing Update (CAP) as it relates to convertible bond terms and pricing adjustments, which are financing activities and capital structure matters.
2025-11-03 Chinese
第五届董事会第三十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 35th meeting of the 5th Board of Directors of the company. It details the meeting attendance, the agenda discussed, and the voting results on a specific matter related to convertible bond conversion price adjustment. It does not contain financial statements or detailed financial data, nor is it a full report. It is a formal announcement of board decisions, specifically about a board meeting resolution. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2025-11-03 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.